Evolus (FRA:EVL) Asset Impairment Charge : €0.0 Mil (TTM As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Evolus Asset Impairment Charge?

Evolus's Asset Impairment Charge for the three months ended in Sep. 2024 was €0.0 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Sep. 2024 was €0.0 Mil.

Evolus Asset Impairment Charge Historical Data

The historical data trend for Evolus's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evolus Asset Impairment Charge Chart

Evolus Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Asset Impairment Charge

Get a 7-Day Free Trial

Evolus Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Asset Impairment Charge	Get a 7-Day Free Trial															-	-	-	-	-

Evolus Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

Evolus Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Evolus's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Evolus Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evolus Inc (FRA:EVL) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

EOLS:USA 0K16:UK

Address

520 Newport Center Drive, Suite 1200, Newport Beach, CA, USA, 92660

Website

https://www.evolus.com

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

Evolus Headlines

No Headlines